Experimental MS drug prevents relapses in nine out of 10 patients

A UC San Francisco-led study found that ofatumumab, a drug that targets immune B cells, reduced relapses by half in the first year. In the second, attacks stopped altogether most patients.

from U.S. Home | Mail Online https://ift.tt/33v3piB
via Top U.S. Stories